Consequently, this new option was almost immediately investigated in the field of BBN-like radioligands, directed to the gastrin-releasing peptide receptor (GRPR) detected in many frequently occurring tumors, especially in prostate and mammary carcinoma [12]. This evidence concerns the gene GRPR and breast carcinoma.